全球抗糖尿病药物研发现状及市场分析

Status Quo of Drugs R&D for Anti-diabetes Mellitus and Analysis of Global Sales

目的:为开发新一代抗糖尿病药物提供新的思路。方法:利用文献调研、网络调研、专家咨询等方法,系统整理和归纳了抗糖尿病药物的在研数量、抗2型糖尿病药物的主要研发公司及研发药物数量和2006-2010年抗糖尿病药物的市场销售额,分析目前全球抗糖尿病药物的研发现状及不同种类药物的市场表现。结果与结论:截至2012年3月,共有400多种抗2型糖尿病药物处于临床试验阶段,默克公司研发的药物数量较多,其次为辉瑞、葛兰素史克、罗氏、礼来、诺和诺德等公司。2010年抗糖尿病药物全球销售额达344.29亿美元,比2009年304.06亿元的销售额增长了12.2%,比2006年213.10亿美元的销售额增长了68.2%。胰岛素和胰岛素类似物所占市场份额最高,且保持了逐年增长的趋势;口服药物中促胰岛素分泌剂市场保持了较高的增长势头;同时随着二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂、胰高血糖素样肽1(GLP-1)类似物等疗效更佳、副作用更小的新型口服促胰岛素分泌剂的上市,格列奈类药物的市场份额正在逐渐减小。DPP-Ⅳ抑制剂、GLP-1类似物、胰高血糖素受体拮抗药、钠-葡萄糖协同转运蛋白2抑制剂等为当下新一代抗2型糖尿病药物研究的重点。

OBJECTIVE:To provide new idea for the development for new generation anti-diabetic drugs.METHODS:By literature survey,network survey and expert consultation,the number of anti-diabetic drugs being developed and drugs for type 2 diabetic of main R&D enterprises in the study,and market share of anti-diabetic drugs during 2006-2010 were summarized systematically.The status quo of the R&D of anti-diabetic drugs in the whole world and sales data of different types of drugs were analyzed.RESULTS & CONCLUSIONS:Up to Mar.2012,a total of 400 kinds of drugs for type 2 diabetic were still at the clinical trial stage.Merck corporation had developed a large number of drugs,followed by Pfizer corporation,GlaxoSmithKline corporation,Roche corporation,Lilly corporation and Novo Nordisk corporation,etc.The consumption sum of anti-diabetic drugs reached 34.429 billion dollars in 2010,increased by 12.2% compared to 30.406 billion dollars in 2009,and by 68.2% compared to 21.310 billion dollars in 2006.Among all the drugs,insulin and insulin analogues took the biggest share of the anti-diabetic market,showing increasing year by year.Insulin sensitizer drugs sold best among oral anti-diabetic drugs,and showed better therapeutic efficacy after combining with dipeptidyl peptidase-Ⅳ(DPP-Ⅳ) inhibitor and Glucagon-like peptide-1(GLP-1) analogues.With the sale of new oral insulin sensitizer drugs with little side effect,nateglinide took up smaller proportion.The points of research of new generation drugs for type 2 diabetic focus on DPP-Ⅳ inhibitor,GLP-1 analogues,glucagon receptor antagonist and sodium-glucose cotransporter 2 inhibitor,etc.